Logo

AVTX

Avalo Therapeutics, Inc.

AVTX

Avalo Therapeutics, Inc. • NASDAQ
$19.00 ▲ 2.43% (+0.45)
Market Cap $214.59 M
52w High $19.41
52w Low $3.39
Dividend Yield 0%
P/E -1.42
Volume 187.67K
Outstanding Shares 11.29M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $19.198M ▼ $-30.625M ▼ 0% $-2.19 ▼ $-30.555M ▼
Q2-2025 $0 $19.316M ▲ $-20.765M ▼ 0% $-1.92 ▼ $-19.182M ▼
Q1-2025 $0 ▼ $14.669M ▲ $-13.149M ▲ 0% ▲ $-1.25 ▼ $-14.534M ▼
Q4-2024 $192K ▼ $13.416M ▼ $-35.339M ▼ -18.406K% ▼ $13.89 ▲ $-13.243M ▼
Q3-2024 $249K $13.824M $23.037M 9.252K% $2.83 $-12.827M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $111.617M ▼ $125.1M ▼ $33.553M ▲ $91.547M ▼
Q2-2025 $113.262M ▼ $126.583M ▼ $22.009M ▲ $104.574M ▼
Q1-2025 $125.046M ▼ $138.523M ▼ $15.908M ▼ $122.615M ▼
Q4-2024 $134.546M ▲ $150.732M ▲ $17.7M ▼ $133.032M ▲
Q3-2024 $81.858M $98.455M $77.379M $21.076M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-30.625M ▼ $-16.365M ▼ $-13.261M ▲ $14.369M ▲ $-15.257M ▲ $-16.365M ▼
Q2-2025 $-20.765M ▼ $-11.39M ▼ $-70.86M ▼ $-469K ▼ $-82.798M ▼ $-11.39M ▼
Q1-2025 $-13.149M ▲ $-9.457M ▲ $0 $0 ▼ $-9.457M ▼ $-9.457M ▲
Q4-2024 $-35.339M ▼ $-15.044M ▼ $0 $67.709M ▲ $52.666M ▲ $-15.044M ▼
Q3-2024 $23.037M $-11.527M $0 $0 $-11.527M $-11.527M

Revenue by Products

Product Q3-2023Q4-2023Q3-2024Q4-2024
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲
License
License
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Avalo is essentially a pre‑revenue biotech. Reported revenue over the past several years is negligible, so the business is not yet commercially driven and depends on external funding rather than product sales. Operating costs, mainly research and corporate overhead, have produced steady losses each year. Those losses appear to be getting somewhat smaller over time, but they are still meaningful relative to the company’s very small size. Per‑share loss figures look extreme mainly because of large reverse stock splits, not because the underlying business suddenly changed overnight.

Balance Sheet

Balance Sheet The balance sheet is very small and quite simple: most assets are cash, with little in the way of physical assets or receivables, which is typical for a clinical‑stage biotech. Reported debt has dropped to minimal levels, so the capital structure is now mostly equity. Equity itself is thin, reflecting a history of accumulated losses and repeated equity issuances. The reverse splits in recent years signal that the company has had to manage a low share price and likely relies heavily on the equity markets for funding. Overall, the balance sheet provides some flexibility through cash on hand but leaves limited room for prolonged setbacks without new capital.

Cash Flow

Cash Flow Cash flow shows a classic early‑stage biotech pattern: consistent cash outflows from operations and essentially no spending on long‑lived assets. The company is burning cash each year to fund trials and overhead, though the burn seems to be moderating somewhat. Free cash flow is negative and closely tracks operating cash use, underscoring that the business is not self‑funding. Management’s stated runway into the later part of the decade implies that additional capital has been or will be raised beyond what’s visible in the historical figures, and future trial decisions will likely be paced to that cash constraint.

Competitive Edge

Competitive Edge Avalo operates in a highly competitive corner of immunology and inflammatory disease, where it faces much larger pharmaceutical and biotech companies with approved products and deeper resources. Its main differentiator is a highly focused strategy around a single lead antibody, AVTX‑009, in diseases where existing treatments leave many patients underserved, starting with hidradenitis suppurativa. The molecule’s very high potency, specific targeting, and potentially convenient dosing schedule could offer an edge if clinical data remain strong. However, depending so heavily on one program creates concentration risk: setbacks in the lead trial or stronger‑than‑expected performance from rival IL‑1 pathway therapies could quickly erode its competitive standing.

Innovation and R&D

Innovation and R&D R&D is concentrated on AVTX‑009, an in‑licensed antibody originally developed by a large pharma company, which brings de‑risking from prior work but also limits Avalo’s control over the underlying intellectual property framework. Scientifically, AVTX‑009 is designed to bind very tightly and specifically to IL‑1β, a well‑validated driver of inflammation, with a drug profile that may allow less frequent dosing and a cleaner safety profile than broader pathway blockers. Strategically, Avalo is pursuing a “pipeline in a product” approach: prove the drug in hidradenitis suppurativa through the ongoing LOTUS Phase 2 trial, then potentially expand into at least one more chronic inflammatory condition. The company has streamlined or paused other programs to conserve resources, which sharpens focus but further increases reliance on one key readout in the middle of the decade.

Summary

Avalo is a tiny, focused, clinical‑stage biotech that has reshaped itself around one main immunology asset. Financially, it has no meaningful revenue, runs regular losses, and consumes cash to advance trials, with a balance sheet that is dominated by cash and a history of equity‑driven funding and reverse splits. Scientifically, its lead antibody looks differentiated on paper—highly potent, specific, and convenient to dose—in an area of real medical need and active pharma interest. The story is therefore highly binary: success in the upcoming Phase 2 trial and any follow‑on indications could transform the company’s profile, while clinical or competitive setbacks would be felt quickly given the narrow pipeline and modest capital base. Uncertainty is high, and the company’s future will largely be determined by clinical data and its ability to secure sufficient funding on acceptable terms.

NEWS

November 17, 2025 · 4:30 PM UTC

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 6, 2025 · 7:00 AM UTC

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Read more

November 3, 2025 · 7:00 AM UTC

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Read more

October 29, 2025 · 7:00 AM UTC

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Read more

October 1, 2025 · 7:00 AM UTC

Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

Read more